XML 59 R21.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Contingencies | 12 Months Ended
--- | ---
Dec. 31, 2021
Contingencies [Abstract] |
Contingencies | Contingencies Assumption Agreement In 1999, we entered into an agreement that assumed certain obligations (the “Assumption Agreement”) in connection with a Share Purchase Agreement (the “Share Purchase Agreement”) between SYNSORB and our former shareholders to make milestone payments and royalty payments. As of December 31, 2021, a milestone payment was still outstanding for $1.0 million, due within 90 days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep. This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes. In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep. If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders 10.75% (2020 - 10.75%) of the royalty payments and other payments received. Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of 2.15% (2020 - 2.15%) of Net Sales received for such products. BRI “Work in Kind” Contribution We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (“BRI”). The terms of this agreement include a “work in kind” contribution from BRI. In exchange for this “work in kind” contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue at the lesser of 0.5% of Sales Revenue or $20,000 per year until December 31, 2028.

X
- Definition The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 37 -IssueDate 2021-01-01 -Paragraph 86 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfContingentLiabilitiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingencies [Abstract] + References No definition available. + Details
Name: | oncyf_ContingenciesAbstract
Namespace Prefix: | oncyf_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration